Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: A cross-sectional study

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 64-75

  Fonseca Camarillo, G ^a,b   Furuzawa Carballeda, J ^b   Granados, J ^c   Yamamoto Furusho, J K ^a  

^a Department of Gastroenterology   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Crohn's disease; IL 24; Interleukin (IL) 19; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 19; INTERLEUKIN 24; MERCAPTOPURINE; MESALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL SURVIVAL; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

CROHN'S DISEASE; IL-24; INTERLEUKIN (IL)-19; ULCERATIVE COLITIS;

ADULT; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELLS, CULTURED; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKINS; MALE; MEXICO; MIDDLE AGED;

EID: 84904243497     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12285     Document Type: Article

References (29)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
2. Fonseca-Camarillo G, Yamamoto-Furusho JK. Interleukins involved in inflammatory bowel disease as new therapeutic targets. Curr Immunol Rev 2013; 9:86-92.
3. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121:1108-1111.
4. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev 2010; 21:315-324.
5. Gallagher G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth Factor Rev 2010; 21:345-352.
6. Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets 2011; 15:119-126.
7. Gallagher G, Dickensheets H, Eskdale J etal. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000; 1:442-450.
8. Liao YC, Liang WG, Chen FW etal. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 2002; 169:4288-4297.
9. Parrish-Novak J, Xu W, Brender T etal. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002; 277:47517-47523.
10. Wolk K, Witte E, Warszawska K etal. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009; 39:3570-3581.
11. Liao SC, Cheng YC, Wang YC etal. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 2004; 173:6712-6718.
12. Gallagher G, Eksdale J, Jordan W etal. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 2004; 4:615-626.
13. Ghoreschi K, Thomas P, Breit S etal. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9:40-46.
14. Azuma YT, Matsuo Y, Kuwamura M etal. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis 2010; 16:1017-1028.
15. Hsing CH, Li HH, Hsu YH etal. The distribution of interleukin-19 in healthy and neoplastic tissue. Cytokine 2008; 44:221-228.
16. Azuma YT, Matsuo Y, Nakajima H. Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection. J Pharmacol Sci 2011; 115:105-111.
17. Andoh A, Shioya M, Nishida A etal. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol 2009; 183:687-695.
18. Emdad L, Lebedeva IV, Su VV etal. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of MDA-7/IL-24. Cancer Biol Ther 2009; 8:391-400.
19. Sahoo A, Im SH. Molecular mechanisms governing IL-24 gene expression. Immune Net 2012; 12:1-7.
20. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29:669-674.
21. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625-1629.
22. Henriksen M, Jahnsen J, Lygren I etal. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006; 12:543-550.
23. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40:35-53.
24. Fickenscher H, Hor S, Kupers H etal. The interleukin-10 family of cytokines. Trends Immunol 2002; 23:89-96.
25. Pestka S, Krause CD, Sarkar D etal. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22:929-979.
26. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002; 13:223-240.
27. Conti P, Kempuraj D, Frydas S etal. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol Lett 2003; 88:171-174.
28. Ellison S, Gabunia K, Kelemen SE etal. Attenuation of experimental atherosclerosis by interleukin-19. Arterioscler Thromb Vasc Biol 2013; 33:2316-2324.
29. Panneerselvam J, Munshi A, Ramersh R. Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities. J Mol Signal 2013; 8:1-15.